Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: BIOLOGICAL: pembrolizumab|DRUG: paclitaxel|DRUG: nab-paclitaxel|DRUG: liposomal doxorubicin|DRUG: capecitabine|DRUG: normal saline|DRUG: dextrose
Sponsor: Merck Sharp & Dohme LLC